×
About 255 results

ALLMedicine™ First-degree Atrioventricular Block Center

Research & Reviews  68 results

Adalimumab for the treatment of cardiac sarcoidosis with multiple arrhythmias.
https://doi.org/10.1002/ehf2.14133
ESC Heart Failure; Li S, Wang H et. al.

Sep 1st, 2022 - A 45-year-old male with cardiac sarcoidosis verified by cardiac biopsy presented with multiple coexisting arrhythmias, including ventricular tachycardia of more than 1000 episodes per 24 h, paroxysmal atrial fibrillation, and third-degree atrioven...

First-Degree Atrioventricular Block
https://emedicine.medscape.com/article/161829-overview

Jul 27th, 2022 - Background First-degree atrioventricular (AV) block, or first-degree heart block, is defined as prolongation of the PR interval on an electrocardiogram (ECG) to more than 200 msec. [1, 2] The PR interval of the surface ECG is measured from the ons...

First-Degree Atrioventricular Block
http://emedicine.medscape.com/article/161829-overview

Jul 27th, 2022 - Background First-degree atrioventricular (AV) block, or first-degree heart block, is defined as prolongation of the PR interval on an electrocardiogram (ECG) to more than 200 msec. [1, 2] The PR interval of the surface ECG is measured from the ons...

First-Degree Atrioventricular Block
https://emedicine.medscape.com/article/161829-print

Jul 27th, 2022 - Background First-degree atrioventricular (AV) block, or first-degree heart block, is defined as prolongation of the PR interval on an electrocardiogram (ECG) to more than 200 msec.[1, 2] The PR interval of the surface ECG is measured from the onse...

Atrioventricular Block Workup
http://emedicine.medscape.com/article/151597-workup

Jul 13th, 2022 - Approach Considerations A review of the patient's comorbidities and medications is essential, as oftentimes these individuals have underlying structural heart disease or coronary artery disease, or they may be taking atrioventricular (AV) node–blo...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  3 results

Dose of Magnesium Sulfate Infusion in Obese
https://clinicaltrials.gov/ct2/show/NCT04645719

Mar 3rd, 2022 - After approval by the Research Ethics Committee and registration of the project at ClinicalTrials (www.ClinicalTrials.gov) 75 patients will be selected from a population of obese patients scheduled for laparoscopic, bariatric or cholecystectomy su...

ReachPR Trial Resynchronization Therapy in Heart Failure Patients With Prolonged PR Interval
https://clinicaltrials.gov/ct2/show/NCT03973944

Aug 14th, 2019 - Rationale: Prolongation of the electrocardiographic PR interval (PR interval > 200ms; also known as first-degree atrioventricular block) is frequently encountered in clinical practice and is generally considered as a benign sign. However, there is...

Cohort Description of Younger With AV-block
https://clinicaltrials.gov/ct2/show/NCT03024047

Jan 18th, 2017 - Method: The following covariates will be reported. Date of diagnosis of AV-block: The date of diagnosis is defined as the day the physician diagnoses the AV-block. E.g. if the patient has a Holter monitoring performed, the date of diagnosis is the...

see more →

News  14 results

Ibrutinib/Rituximab Combo Represents Effective Chemo-Free Option for Elderly Patients with MCL
https://www.onclive.com/view/ibrutinib-rituximab-combo-represents-effective-chemo-free-option-for-elderly-patients-with-mcl

Jan 14th, 2022 - The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced a high overall response rate (ORR) and durable survival in elderly patients with mantle cell lymphoma (MCL), according to data from a phase 2 ENRICH trial (NCT0180567) publi...

One Aducanumab Patient, Six Brain Edema Episodes
https://www.medpagetoday.com/neurology/alzheimersdisease/95523

Nov 8th, 2021 - A man treated with the recently approved Alzheimer's drug aducanumab (Aduhelm) had six amyloid-related imaging abnormality (ARIA) episodes, researchers reported. Over 44 months in a long-term extension study, the Alzheimer's disease patient had re...

Relapsing MS: Ozanimod Tops Fingolimod in Benefit-Risk Profile
https://www.mdedge.com/neurology/msresourcecenter/article/217365/multiple-sclerosis/relapsing-ms-ozanimod-tops-fingolimod?channel=251

Feb 14th, 2020 - Key clinical point: Ozanimod has a superior benefit-risk profile compared with fingolimod for the treatment of relapsing multiple sclerosis (RMS). Major finding: Compared with fingolimod, ozanimod was associated with lower rates of conduction abno.

Relapsing MS: Ozanimod Tops Fingolimod in Benefit-Risk Profile
https://www.mdedge.com/neurology/msresourcecenter/article/217365/multiple-sclerosis/relapsing-ms-ozanimod-tops-fingolimod

Feb 14th, 2020 - Key clinical point: Ozanimod has a superior benefit-risk profile compared with fingolimod for the treatment of relapsing multiple sclerosis (RMS). Major finding: Compared with fingolimod, ozanimod was associated with lower rates of conduction abno.

Mohs Micrographic Surgery Overlying a Pacemaker
https://www.mdedge.com/dermatology/article/178721/nonmelanoma-skin-cancer/mohs-micrographic-surgery-overlying-pacemaker
Joshua E. Lane, MD, MBA, Andrew C. Anderson, DO, PharmD

Nov 1st, 2018 - To the Editor: Pacemakers and defibrillators are common in patients presenting for cutaneous surgery. The use and application of electrosurgery in this patient population has been reviewed extensively.

see more →